Chikungunya vaccine enters Phase I clinical trial
by Press Release from Outbreak News Today on (#3J74E)
Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, announced the initiation of a Phase I clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1553, its live-attenuated vaccine candidate against Chikungunya. The Phase I clinical trial is a randomized, observer-blinded, dose-escalation, multi-center study. It will ["]
The post Chikungunya vaccine enters Phase I clinical trial appeared first on Outbreak News Today.